# Study of Favezelimab (MK-4280) as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib (MK-7902) AND Favezelimab/Pembrolizumab (MK-4280A) as Monotherapy in Adults With Advanced Solid Tumors (MK-4280-001)

> **NCT02720068** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 481 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **BIOLOGICAL:** Favezelimab
- **BIOLOGICAL:** Pembrolizumab
- **DRUG:** Oxaliplatin
- **DRUG:** Irinotecan
- **DRUG:** Leucovorin (Calcium Folinate)
- **DRUG:** Fluorouracil [5-FU]
- **BIOLOGICAL:** Favezelimab/Pembrolizumab
- **DRUG:** Lenvatinib

## Key facts

- **NCT ID:** NCT02720068
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05-02
- **Primary completion:** 2024-03-15
- **Final completion:** 2024-03-15
- **Target enrollment:** 481 (ACTUAL)
- **Last updated:** 2025-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02720068

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02720068, "Study of Favezelimab (MK-4280) as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib (MK-7902) AND Favezelimab/Pembrolizumab (MK-4280A) as Monotherapy in Adults With Advanced Solid Tumors (MK-4280-001)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02720068. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*